NL-1
目录号 : GC39411
The mitochondrial mitoNEET ligand NL-1 is a mitoNEET inhibitor, which induces a concentration-dependent decrease in cell viability with an IC50 of 47.35 μM and 56.26 μM in REH and REH/Ara-C cells respectively. The docking studies using liver mitochondrial suspensions show the IC50 of NL-1 binding for [3H]-rosiglitazone is 0.9 μM and the Ki for NL-1 site 1 and site 2 was 4.78 and 2.77, respectively.
Cas No.:188532-26-5
Sample solution is provided at 25 µL, 10mM.
;)
_1-7.$$$37316672@70.jpg');)
;)
;)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
;)
;)
;)
_1124-1138.$$$35908550@30.jpg');)
_766-780.$$$37100057@30.jpg');)
_418-432.$$$36893736@30.jpg');)
_240-255.$$$35108512@29.jpg');)
_533-545.$$$36543525@28.jpg');)
_264-276.$$$36600053@22.jpg');)
_2214998.$$$@0.jpg');)
The mitochondrial mitoNEET ligand NL-1 is a mitoNEET inhibitor, which induces a concentration-dependent decrease in cell viability with an IC50 of 47.35 μM and 56.26 μM in REH and REH/Ara-C cells respectively. The docking studies using liver mitochondrial suspensions show the IC50 of NL-1 binding for [3H]-rosiglitazone is 0.9 μM and the Ki for NL-1 site 1 and site 2 was 4.78 and 2.77, respectively.
NL-1 is a mitoNEET inhibitor with antileukemic effect, which induces a concentration-dependent decrease in cell viability of REH and REH/Ara-C, and impaires the migratory ability of leukemic cells irrespective of the chemoattractant used.[2]
NL-1 shows antileukemic activity in an in vivo mouse ALL model.[2]
[1] Geldenhuys WJ, et al. Bioorg Med Chem Lett. 2010 Feb 1;20(3):819-23. [2] Geldenhuys WJ, et al. J Pharmacol Exp Ther. 2019 Jul;370(1):25-34.
| Cas No. | 188532-26-5 | SDF | |
| Canonical SMILES | O=C(N1)SC(CC2=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C2)C1=O | ||
| 分子式 | C18H25NO3S | 分子量 | 335.46 |
| 溶解度 | DMSO: 250 mg/mL (745.25 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.981 mL | 14.9049 mL | 29.8098 mL |
| 5 mM | 0.5962 mL | 2.981 mL | 5.962 mL |
| 10 mM | 0.2981 mL | 1.4905 mL | 2.981 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet